Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The Chemours Company reported its third-quarter 2025 financial results, emphasizing significant achievements and ongoing challenges.</li><li>The company surpassed its adjusted EBITDA expectations despite ongoing macroeconomic challenges, particularly in sectors sensitive to economic fluctuations.</li><li>A focal point of success was the Thermal & Specialized Solutions (TSS) segment, where revenue from Opteon refrigerants surged by 80% compared to the previous year.</li></ul>

The Chemours Company reported its third-quarter 2025 financial results, emphasizing significant achievements and ongoing challenges.The company surpassed its adjusted EBITDA expectations despite ongoing macroeconomic challenges, particularly in sectors sensitive to economic fluctuations.A focal point of success was the Thermal & Specialized Solutions (TSS) segment, where revenue from Opteon refrigerants surged by 80% compared to the previous year.

ケマーズ：オプテオンの 80% 急上昇が冷媒の成長ストーリーを書き換え、成長の道のりは投資家の予想より長くなる可能性あり！

Chemours Co/The

ケマーズ：オプテオンの 80% 急上昇が冷媒の成長ストーリーを書き換え、成長の道のりは投資家の予想より長くなる可能性あり！